Clinical trial · no report yet · Phase 2/Phase 3
STELLAR-311
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- NCT06943755 ↗
- Recruiting
- Exelixis
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions
- Zanzalintinib; Everolimus
- Arms
- Everolimus · Active comparator
- Zanzalintinib · Experimental
- Enrollment
- 440 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Exelixis
- Start
- Jul 21, 2025
- Primary completion
- Jun 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06943755 · updated Sep 29, 2026
Publications
linked from the registry- Chan JA, Strosberg JR, Yoo C, Singh S, Huang H, Goel M, Scheffold C, Capdevila J. STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors. Future Oncol. 2026 Sep 28:1-8. doi: 10.1080/14796694.2026.2733790. Online ahead of print. PubMed 42803451